Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Development Status

US Previously Marketed

4

All Match

Any Match

Exclude Selected

Exclude Selected

Primary Target

regulation of blood coagulation

4

All Match

Any Match

Exclude Selected

Exclude Selected

Highest Phase

Approved

4

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

1941

4

All Match

Any Match

Exclude Selected

Exclude Selected

Condition

Correction of coagulopathy associated with cholestasis

4

Excessive bleeding

4

All Match

Any Match

Exclude Selected

Exclude Selected

Treatment Modality

Preventive

4

Secondary

4

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Chemical

4

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

CAS

4

EPA CompTox

4

FDA UNII

4

PUBCHEM

4

SMS_ID

4

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Salts, Hydrates, Esters, etc.

3

Principal Form

1

All Match

Any Match

Exclude Selected

Exclude Selected

Showing 1 - 4 of 4 results

First page disabled
Previous page disabled
1
Next page disabled
Next page disabled

MENADIOL

VQ093653DO

Export Data
Search for Structure

Status:

US Previously Marketed

First approved in 1941

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

regulation of blood coagulation

Conditions:

Excessive bleeding

Correction of coagulopathy associated with cholestasis

Menadiol is one of the forms of vitamin K4. Chemically, it is closely related to menadione. Oral menadiol appears to be an effectiv ealternative to intravenous phytomenadione in the correction of coagulopathies associated with obstructiveliver diseas...

e. This simplifies the care of patients with deranged clotting times requiring cholangeopancrea-tography, particularly those to be managed as out-patients. Menadiol should receive clinical testing as a chemosensitizing agent in human lymphatic neoplasms (HLN). This effect occurred at a concentration (2.0 micrograms/ml; 4.7 microM) of menadiol which is probably clinically achievable and which did not deplete intracellular glutathione.

MENADIOL SODIUM DIPHOSPHATE ANHYDROUS

R2L46WE615

Export Data
Search for Structure

Status:

US Previously Marketed

First approved in 1941

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

regulation of blood coagulation

Conditions:

Excessive bleeding

Correction of coagulopathy associated with cholestasis

Menadiol is one of the forms of vitamin K4. Chemically, it is closely related to menadione. Oral menadiol appears to be an effectiv ealternative to intravenous phytomenadione in the correction of coagulopathies associated with obstructiveliver diseas...

e. This simplifies the care of patients with deranged clotting times requiring cholangeopancrea-tography, particularly those to be managed as out-patients. Menadiol should receive clinical testing as a chemosensitizing agent in human lymphatic neoplasms (HLN). This effect occurred at a concentration (2.0 micrograms/ml; 4.7 microM) of menadiol which is probably clinically achievable and which did not deplete intracellular glutathione.

MENADIOL DIPHOSPHATE

GRL65FEU3T

Export Data
Search for Structure

Status:

US Previously Marketed

First approved in 1941

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

regulation of blood coagulation

Conditions:

Excessive bleeding

Correction of coagulopathy associated with cholestasis

Menadiol is one of the forms of vitamin K4. Chemically, it is closely related to menadione. Oral menadiol appears to be an effectiv ealternative to intravenous phytomenadione in the correction of coagulopathies associated with obstructiveliver diseas...

e. This simplifies the care of patients with deranged clotting times requiring cholangeopancrea-tography, particularly those to be managed as out-patients. Menadiol should receive clinical testing as a chemosensitizing agent in human lymphatic neoplasms (HLN). This effect occurred at a concentration (2.0 micrograms/ml; 4.7 microM) of menadiol which is probably clinically achievable and which did not deplete intracellular glutathione.

MENADIOL SODIUM DIPHOSPHATE

2OVL75B30W

Export Data
Search for Structure

Status:

US Previously Marketed

First approved in 1941

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

regulation of blood coagulation

Conditions:

Excessive bleeding

Correction of coagulopathy associated with cholestasis

Menadiol is one of the forms of vitamin K4. Chemically, it is closely related to menadione. Oral menadiol appears to be an effectiv ealternative to intravenous phytomenadione in the correction of coagulopathies associated with obstructiveliver diseas...

e. This simplifies the care of patients with deranged clotting times requiring cholangeopancrea-tography, particularly those to be managed as out-patients. Menadiol should receive clinical testing as a chemosensitizing agent in human lymphatic neoplasms (HLN). This effect occurred at a concentration (2.0 micrograms/ml; 4.7 microM) of menadiol which is probably clinically achievable and which did not deplete intracellular glutathione.

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1